Trending NewsTrending NewsNASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis $88.98 +1.73 (+1.98%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Spyre Therapeutics Stock (NASDAQ:SYRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spyre Therapeutics alerts:Sign Up Key Stats Today's Range$84.68▼$89.1850-Day Range$86.63▼$108.9252-Week Range$14.51▼$110.18Volume803,823 shsAverage Volume1.09 million shsMarket Capitalization$7.82 billionP/E RatioN/ADividend YieldN/APrice Target$109.69Consensus RatingModerate Buy Company Overview Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications. Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts. The company utilizes advanced screening technologies and a modular engineering approach to optimize therapeutic candidates, streamline preclinical development and position its programs for clinical readiness. Based in the United States, Spyre Therapeutics operates a modern research and development facility that supports both in-house projects and external partnerships. Led by a management team experienced in biopharmaceutical innovation and development, the company is working to advance its lead programs into human trials and aims to bring new treatment options to patients with high-need cancers.AI Generated. May Contain Errors. Read More Spyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreSYRE MarketRank™: Spyre Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 495th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingSpyre Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 1 strong buy rating, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSpyre Therapeutics has a consensus price target of $109.69, representing about 23.3% upside from its current price of $88.98.Amount of Analyst CoverageSpyre Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.62) to ($3.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyre Therapeutics is -45.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyre Therapeutics is -45.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpyre Therapeutics has a P/B Ratio of 8.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Spyre Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.86% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 15.95, which indicates bearish sentiment.Change versus previous monthShort interest in Spyre Therapeutics has recently decreased by 3.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.36 News SentimentSpyre Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Spyre Therapeutics this week, compared to 5 articles on an average week.MarketBeat FollowsOnly 2 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,638,714.00 in company stock.Percentage Held by Insiders15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spyre Therapeutics' insider trading history. Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRE Stock News HeadlinesSpyre Therapeutics Announces Grants of Inducement AwardsSeptember 4 at 4:01 PM | globenewswire.comSpyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 400 Shares of StockSeptember 4 at 7:22 AM | insidertrades.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 6 at 1:00 AM | Porter & Company (Ad)Spyre Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 3 at 4:05 PM | globenewswire.comSpyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just WorkedSeptember 1, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)August 30, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Argenx Se (ARGX) and Spyre Therapeutics (SYRE)August 28, 2026 | theglobeandmail.comScott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockAugust 6, 2026 | insidertrades.comSee More Headlines SYRE Stock Analysis - Frequently Asked Questions How have SYRE shares performed this year? Spyre Therapeutics' stock was trading at $32.76 at the beginning of the year. Since then, SYRE shares have increased by 171.6% and is now trading at $88.98. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.40. When did Spyre Therapeutics IPO? Spyre Therapeutics (SYRE) raised $85 million in an IPO on Wednesday, April 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Who are Spyre Therapeutics' major shareholders? Top institutional investors of Spyre Therapeutics include California State Teachers Retirement System (6.53%), Wellington Management Group LLP (1.80%), Braidwell LP (1.00%) and Bank of New York Mellon Corp (0.28%). Insiders that own company stock include Cameron Turtle, Scott L Burrows, Michael Thomas Henderson, Sheldon Sloan, Jeffrey W Albers, Heidy King-Jones and Fairmount Funds Management Llc. View institutional ownership trends. How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/04/2026Today9/06/2026Citigroup’s Biopharma Back to School Summit 20269/09/2026Wells Fargo 21st Annual Healthcare Conference9/10/2026Stifel 2026 Virtual Immunology and Inflammation Forum9/23/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SYRE's financial health is in the Green zone, according to TradeSmith. SYRE has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CIK1636282 Webwww.aeglea.com Phone512-942-2935Fax512-872-5121Employees73Year FoundedN/APrice Target and Rating Average Price Target for Spyre Therapeutics$109.69 High Price Target$130.00 Low Price Target$80.00 Potential Upside/Downside+23.3%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$155.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.74% Return on Assets-22.23% Debt Debt-to-Equity RatioN/A Current Ratio18.53 Quick Ratio18.53 Sales & Book Value Annual Sales$890 thousand Price / Sales8,792.02 Cash FlowN/A Price / Cash FlowN/A Book Value$10.86 per share Price / Book8.19Miscellaneous Outstanding Shares87,940,000Free Float74,139,000Market Cap$7.82 billion OptionableOptionable Beta2.99 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SYRE) was last updated on 9/6/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredBefore the Market Opens After Labor Day ...Uber fell 40% within six months of its IPO. Meta dropped nearly 50% in three months, and Robinhood plunged 85%...Weiss Ratings | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredThis sub-5 dollar stock operates next to SpaceX and Blue OriginA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
